Metraipolis › archive › dc_2baf84a885cf

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and… — Europe PMC PMID:42494530

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42494530
DOI
10.3389/fphar.2026.1887454
License (as archived)
solo-consultazione
Archived
2026-10-18T09:39:26.124Z
SHA-256 of the archived text
1a3a9c1f46af087b29cee722d9d6fa7fe706a263dd28585b90adc7a3ed68293f
Stable URL of this page
https://metraipolis.com/documento/dc_2baf84a885cf

How to cite

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and… — Europe PMC PMID:42494530 — Europe PMC (en), https://europepmc.org/article/MED/42494530 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2baf84a885cf (Metraipolis archive dc_2baf84a885cf, sha256 1a3a9c1f46af087b29cee722d9d6fa7fe706a263dd28585b90adc7a3ed68293f)
BibTeX
@misc{dc2baf84a885cf,
  title = {Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and… — Europe PMC PMID:42494530},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42494530},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2baf84a885cf; sha256 1a3a9c1f46af087b29cee722d9d6fa7fe706a263dd28585b90adc7a3ed68293f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42494530. Agents can read the archived copy with the MCP tool read_document.